EBV Infection Arrives Early in Costa Rica and Becomes Nearly Universal by Adulthood
Costa Rica’s first population-based look at Epstein-Barr virus seroprevalence shows a pattern that is familiar to infectious disease epidemiology but still clinically consequential: infection is acquired early, then persists quietly for life. In a cohort of 2,990 participants enrolled in 2020 and 2021, antibody positivity climbed with age, exceeded 80% in adolescents, and rose above 90% in adults 20 years and older. By the time adulthood was reached, seropositivity was high in both sexes and across regions of residence.
The practical meaning is straightforward. EBV is not a marginal childhood exposure in this setting; it is a near-universal infection that settles into lifelong latency in B cells and remains relevant long after the initial illness, or lack of one, has passed.
Why Age at Infection Still Matters Clinically
Primary EBV infection is often silent in early childhood, but delayed acquisition can change the clinical picture. When infection occurs later, particularly in adolescence, the probability of symptomatic infectious mononucleosis increases. That matters because EBV is not just a cause of a self-limited febrile syndrome. It has long been tied to lymphoproliferative disease, several malignancies, and more recent work has linked it to multiple sclerosis.
This Costa Rican analysis fits that biology cleanly. The steep rise in seropositivity through childhood and adolescence suggests that exposure accumulates early and then rapidly reaches a plateau. In adults, the high prevalence means most people have already passed through primary infection, leaving little room for prevention strategies focused only on symptomatic disease detection. The more important question becomes how early infection patterns shape later EBV-associated risk.
A single sentence captures the public health reality: adult seropositivity was already above 90%.
Sex and Residence Shaped the Timing of Seroconversion
The study found that the age at seroconversion was slightly younger in boys than in girls. A similar shift appeared by place of residence, with younger seroconversion in rural and mixed areas compared with other settings. These are modest differences, but they point to the influence of social contact patterns, household crowding, school exposure, and other environmental factors that govern when children first encounter the virus.
Among seropositive participants, women tended to have higher geometric mean antibody levels than men. The article does not claim a clinical threshold for those differences, and antibody magnitude alone should not be overread as disease severity or protection. Even so, serologic intensity may reflect differences in immune response, prior reactivation, or cumulative exposure. In a latent herpesvirus with lifelong persistence, antibody patterns are a biological footprint, not a trivial laboratory footnote.
The Cohort Adds Population Context Costa Rica Has Lacked
The analysis used baseline data from the RESPIRA cohort, a population-based study originally designed to examine immune response to SARS-CoV-2 infection. The cohort included an age-stratified sample of 999 PCR-confirmed COVID-19 cases and 1,999 population controls matched on age, sex, and geographic residence. Participants came from regions covering approximately 70% of Costa Rica’s population, giving the EBV findings a broad geographic foundation rather than a clinic-based snapshot.
That design matters because EBV seroepidemiology is highly dependent on local social and economic conditions. In lower-resource settings, infection often occurs earlier; in higher-resource settings, primary infection may be delayed until adolescence or later. Costa Rica sits in a region where such patterns can vary sharply by community, household structure, and access to sanitation and education. Population-based data are the only reliable way to see whether those differences are large enough to influence prevention policy.
Vaccine Planning Depends on Knowing When Infection Happens
No licensed EBV vaccine exists yet, but the field is moving. Early vaccine candidates, including a gp350-based formulation, protected against infectious mononucleosis without preventing infection. Newer formulations aim for stronger immune responses, broader glycoprotein targets, and improved delivery systems. Those developments make age-specific seroprevalence studies more than descriptive epidemiology; they help define the vaccination window.
If most children in a country are infected early, a vaccine would need to be delivered before that exposure occurs to have any realistic chance of preventing infection and the downstream risks tied to latency. If infection clusters in certain neighborhoods, sexes, or age bands, targeted immunization could be more efficient than a broad universal strategy. This Costa Rican cohort suggests that both age and geography deserve attention, even though adult seropositivity eventually converges across groups.
The biological logic is unforgiving. Once EBV establishes lifelong latency, prevention becomes much harder than blocking primary infection in childhood.
What This Study Does and Does Not Answer
The study provides a clear seroepidemiologic map, but it does not measure incident infection prospectively, and it does not connect antibody status to later EBV-associated cancers, autoimmune disease, or infectious mononucleosis in the same participants. It also cannot tell us whether the higher antibody levels seen in women translate into any clinical consequence. Those are separate questions that require longitudinal follow-up, virologic data, and disease-endpoint tracking.
Even with those limits, the findings fill an important gap. Costa Rica now has baseline evidence that EBV acquisition is common, age dependent, and nearly universal by adulthood. For clinicians and public health planners, that means EBV prevention cannot be designed around adult infection alone. The relevant window is earlier, when children are still moving from susceptibility to silent seroconversion, and when a future vaccine would have the best chance to alter the natural history of a virus that never truly goes away.